Arcutis Biotherapeutics. has been granted a patent for a method to enhance the skin penetration of roflumilast. The composition, which includes specific emulsifiers and maintains a pH of 4.0-6.5, aims to reduce lag time, improving bioavailability and onset of relief for patients. GlobalData’s report on Arcutis Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arcutis Biotherapeutics, was a key innovation area identified from patents. Arcutis Biotherapeutics's grant share as of June 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Method to reduce roflumilast skin penetration lag time
The granted patent US12042558B2 outlines a method for enhancing the skin penetration of roflumilast, a medication used in treating skin conditions such as psoriasis and atopic dermatitis. The method involves the topical administration of a specific composition that includes roflumilast in concentrations ranging from 0.005% to 2% w/w, combined with a blend of emulsifiers—cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate—along with diethylene glycol monoethyl ether. Notably, the formulation is designed to avoid the inclusion of hexylene glycol and maintains a pH level between 4.0 and 6.5. The claims emphasize that this composition significantly reduces the skin penetration lag time of roflumilast to less than 60 minutes, with further specifications indicating potential reductions to under 45 minutes.
Additionally, the patent claims highlight the therapeutic applications of this method, specifically targeting patients suffering from psoriasis and atopic dermatitis. The formulation's effectiveness is underscored by its ability to achieve a rapid onset of action, which is critical for managing these skin conditions. The inclusion of isopropyl palmitate in an alternative composition is also mentioned, reinforcing the versatility of the method while adhering to the same parameters regarding roflumilast concentration, pH, and the exclusion of hexylene glycol. Overall, the patent presents a novel approach to improving the delivery and efficacy of roflumilast in topical treatments for specific dermatological disorders.
To know more about GlobalData’s detailed insights on Arcutis Biotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
